Moreover, detailed immunohistochemical analysis of S100A16 in breast cancer patients revealed S100A16 as a compelling biomarker which predicted poorer prognosis and was correlated with both tumor size and increased incidence of lymph node metastasis [14]. Here, S100A16 is linked to metastatic malignant neoplasm in the lymph nodes.